



COPY OF PAPERS
ORIGINALLY FILED

03CD
#3
up attachment

ATTORNEY DOCKET NO. UBC.P-020-3
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gleave, et al.
Serial No. : 10/080,794
Filing Date : February 22, 2002
Title : TRPM-2 Antisense Therapy Using an Oligonucleotide having 2'-O-
(2-methoxy) Ethyl Modifications
Confirmation No. : 2924

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner Patents and Trademarks
Washington, DC 20231

Sir:

Applicant requests that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith. These references were cited on the International Search Report of PCT/US00/04875, a copy of which is also enclosed.

Applicants do not believe fees are due for this submission as we have not received an action on the merits. However, if the Commissioner deems fees are due, the Commissioner is authorized to debit any such fees from Deposit Account Number 15-0610.

Respectfully submitted,
OPPEDAHL & LARSON LLP

Marina T. Larson
Marina T. Larson, PhD, Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
970-468-6600

CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

5/24/02
5/24/02
Date of Signature

Linda L. Orr
Linda L. Orr

Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**



Application No.: 10/080,794

Applicant: Gleave

Filing Date: 02/22/2002

Title: TRPM-2 Antisense Therapy
Using an Oligonucleotide having 2'-
O-(2-methoxy) Ethyl Modifications

COPY OF PAPERS
ORIGINALLY FILED

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS

	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
KAL	Buttayan et al., "Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death" <i>Molecular and Cellular Biology</i> Aug. 1989, Vol. 9, No. 8, pp. 3473-3481
	Millar et al., "Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous epithelium: fact or artefact?" <i>International Journal of Andrology</i> , 17:149-160
	Darby et al., "Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity" <i>Exp Nephrol</i> 1995; 3:234-239
	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays" <i>Nature Biotechnology</i> Volume 15, June 1997, pp. 537-541
	Sensibar et al., "Prevention of Cell Death Induced by Tumor Necrosis Factor alpha in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin)," <i>Cancer Research</i> . June 1, 1995, Vol. 55, pp. 2431-2437
	Miyake et al., "Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer", <i>Cancer Research</i> 60, January 1, 2000, pp. 170-176
	Yang et al., "Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death", <i>Proc. Nat'l. Acad. Sci. USA</i> , Vol. 97, Issue 11, pp 5907-5912, May 23, 2000
✓	Benner, et al., "Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies", <i>Journal of Pharmacological and Toxicological Method</i> , 37:229-235 (1997)

Karen Gleave

05-12-03

Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application No.: 10/080,794

Applicant: Gleave

Filing Date: 02/22/2002

Title: TRPM-2 Antisense Therapy
Using an Oligonucleotide having 2'-
O-(2-methoxy) Ethyl Modifications

Page 2 of 2

KAL	Kadomatsu, et al, "Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle", <i>Cancer Res</i> April 1, 1993, 53(7):1480-1483
J	Kyprianou, et al, "bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells.", <i>Int J Cancer</i> , Jan. 27, 1997, 70(3):341-348
J	Wright, et al, "A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.", <i>Exp Cell Res</i> , Jan. 10, 1996, 222(1):54-60
↓	Bruchovsky, et al., "Control of tumor progression by maintenance of apoptosis.", <i>Prostate Suppl.</i> , 1996, 6:13-21

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Karen A. Jaconiere
Examiner Signature

05-12-03
Date Considered